摘要
过敏原特异性免疫治疗(allergy specific immunotherapy,AIT)由Leonard Noon于1911年首次用于治疗花粉症患者,已成为通过免疫调节机制改变过敏性疾病自然进程的治疗方式,经过百余年的发展,其安全性和有效性得到国内外学者的肯定.目前AIT常用于治疗过敏性鼻炎(allergic rhinitis,AR)和支气管哮喘患者,也有学者将AIT作为食物过敏和特应性皮炎的治疗方式.AIT疗效显著,但是仍有40%的AR和10%~15%的哮喘患者并未完全缓解症状,而且目前尚没有经过验证的生物标志物反映或预测临床疗效,有待进一步的探索.
Allergy specific immunotherapy(AIT)was initiated by Leonard Noon in 1911 for the treatment of patients with hay fever.It is recognized as a therapy that changes the natural course of allergic diseases through immunoregulatory mechanisms.After more than 100 years of development,its safety and effieacy has been recognized by scholars at home and abroad.At present,AIT was used to treat the patients of AR and AS.In recent years,some scholars have used AIT as a treatment for food allergy and atopic dermatitis,but 40%of allergic rhinitis and 10%~20%children with asthma are not effective.There are no validated biomarkers to monitor or predict clinical efficacy,and further explorations are needed.
作者
王亚如(综述)
向莉(审校)
Wang Yaru;Xiang Li(Department of Allergy,Beijing Children′s Hospital,Capital Medical University/National Center for Children′s Health,Beijing 100045,China)
出处
《国际儿科学杂志》
2019年第7期465-468,共4页
International Journal of Pediatrics
基金
北京市自然科学基金资助项目(7172074)
北京市医院管理中心儿科学科协同发展中心专项经费资助(XTCX201818)
